Structural Formula (Letrozole Tablets 01)
Letrozole
Product Images NDC 24535-0801
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 24535-0801). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Arab Pharmaceutical Manufacturing Co. Psc Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 Disease-free Survival (median Follow-up 73 Months, Itt Approach) (Letrozole Tablets 02)
Figure 2 Kaplan-meier Estimates Of Time To Progression (tamoxifen Study) (Letrozole Tablets 03)
Figure 3 Survival By Randomized Treatment Arm (Letrozole Tablets 04)
Figure 4 Kaplan-meier Estimates Of Time To Progression (megestrol Acetate Study) (Letrozole Tablets 05)
Figure 5 Kaplan-meier Estimates Of Time To Progression (aminoglutethimide Study) (Letrozole Tablets 06)
Letrozole is a medication available in tablet form with a strength of 0.5 mg. No additional information is available from the provided text.*
Ndc 24535-0801-1letrozole Tablets, Usp2.5 mgrx Only30 Tablets (Letrozole Tablets 07)
This is a description of a medication containing 25 mg of letozok. The text includes some unclear characters and codes, but it also indicates the name and address of the manufacturer or distributor of the medication.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
